The most relevant comparable study is the randomised study conducted by the GRAALL group,2 which enrolled a cohort with BCR-ABL1-negative acute lymphoblastic leukaemia and with CD20 expression on more than 20% of blasts—the median age was 6 years younger than in our present study. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.